HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

estradiol-drospirenone combination

Subscribe to New Research on estradiol-drospirenone combination

consists of 17beta-estradiol and drospirenone; used to treat menopause

Also Known As:

Angeliq

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Drug Context: Research Results

Polycyclic Compounds: 56
- Steroids: 18537
  - Androstanes: 8
    - Androstenes: 4
      - estradiol-drospirenone combination: 3
  - Estranes
    - Estrenes
      - Estradiol: 10364
        estradiol-drospirenone combination: 3
Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormones: 60571
  - Gonadal Hormones: 363
    - Gonadal Steroid Hormones: 3173
      - Estradiol Congeners: 117
        Estradiol: 10364
        estradiol-drospirenone combination: 3
Pharmaceutical Preparations
- Drug Combinations: 1281
  - estradiol-drospirenone combination: 3

Experts

1.	Oghan, Fatih: 1 article (05/2011)
2.	Keskin, Nadi: 1 article (05/2011)
3.	Coksuer, Hakan: 1 article (05/2011)
4.	Ozveren, Olcay: 1 article (05/2011)
5.	Koplay, Mustafa: 1 article (05/2011)
6.	Coksuer, Cengiz: 1 article (05/2011)
7.	Foidart, J-M: 1 article (10/2005)

Related Diseases

1.	Body Weight (Weight, Body) 10/01/2005 - "Clinical studies with an oral contraceptive containing 30 microg ethinylestradiol and 3 mg drospirenone (Yasmin, Schering AG, Berlin, Germany) and a new continuous combined oral hormone replacement therapy (HRT) containing 1 mg 17beta-estradiol and 2 mg drospirenone (Angeliq, Schering AG) were all designed specifically to evaluate treatment effects on body weight and cardiovascular function, both of which can be influenced by aldosterone receptor antagonism. "
2.	Vertigo (Positional Vertigo) 05/01/2011 - "Oral daily treatment with Angeliq reduces CIMT and climacteric complaints including vertigo/dizziness in postmenopausal women. " 05/01/2011 - "To investigate the effects of Angeliq on hormonal, metabolic, biochemical and cardiovascular profile, carotid intima-media thickness (CIMT) and vertigo/dizziness symptoms in postmenopausal women. "
3.	Hemorrhage 06/16/2015 - "Before treatment, the level of E2 was (12 ± 10) ng/L, triglyceride (TG) (2.0 ± 1.1) mmol/L, lipoprotein-a (LPa) (47 ± 43) mmol/L in group 1 versus (23 ± 12) ng/L, (1.3 ± 0.7) mmol/L and (28 ± 14) mmol/L in group 2. After 12-week treatment, (30 ± 18) ng/L, (1.6 ± 1.1) mmol/L and (37 ± 36) mmol/L in group 1 versus (23 ± 9) ng/L, (1.1 ± 0.6) mmol/L and (18 ± 12) mmol/L in group 2. A greater incidence of vaginal bleeding and thicker endometrium were found in group 1. Angeliq can relieve menopausal symptoms. "
4.	Dizziness (Lightheadedness) 05/01/2011 - "Oral daily treatment with Angeliq reduces CIMT and climacteric complaints including vertigo/dizziness in postmenopausal women. " 05/01/2011 - "To investigate the effects of Angeliq on hormonal, metabolic, biochemical and cardiovascular profile, carotid intima-media thickness (CIMT) and vertigo/dizziness symptoms in postmenopausal women. "

Related Drugs and Biologics

1.	Aldosterone Receptors
2.	drospirenone and ethinyl estradiol combination (Yasmin)
3.	drospirenone
4.	Lipoprotein(a)

Related Therapies and Procedures

1.	Hormone Replacement Therapy (Therapy, Hormone Replacement)